A Randomized Double Blind Placebo Controlled Study Of Celecoxib Add-On In Obsessive Compulsive Disorder
Phase 2
Completed
- Conditions
- Health Condition 1: F422- Mixed obsessional thoughts and acts
- Registration Number
- CTRI/2022/01/039407
- Lead Sponsor
- King George Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 44
Inclusion Criteria
Informed consent from the patient
Diagnosed with OCD (ICD-10 DCR)
Symptomatic (Y-BOCS Score more than or equal to 21)
Drug naive (Drug free period for at least 12 weeks)
Exclusion Criteria
Any other psychiatric comorbidity(Except nicotine dependence)
Any medical condition requiring priority management or where use of COX-2 inhibitors is contraindicated
Patient receiving a course of any immunosuppressive therapy or NSAID in adequate
dose for consecutive 5 days or more in the past 8 weeks.
Established non-response to Fluoxetine (Adequate dose for adequate duration)
Intellectual disability (assessed clinically), Pregnancy and breastfeeding
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method